Glanbia plc (GLAPF)
| Previous Close | 15.94 |
| Open | 15.94 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 15.94 - 15.94 |
| 52 Week Range | 11.00 - 15.94 |
| Volume | |
| Avg. Volume | 188 |
| Market Cap | 4.471B |
| Beta (5Y Monthly) | 0.49 |
| PE Ratio (TTM) | 16.27 |
| EPS (TTM) | 0.98 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.37 (2.30%) |
| Ex-Dividend Date | Aug 24, 2023 |
| 1y Target Est | N/A |
ReutersRipe for change? Activist investors eye food, consumer goods firms
In early 2021, investment management firm Artisan Partners sent an open letter to an incoming member of Danone's board, saying it had built a stake of more than 3% in the French food giant. "On almost every measure, Danone's performance has lagged," Artisan said, and called for change. About a month later, Danone's then-CEO and chairman, Emmanuel Faber, was ousted and its board overhauled in a high-profile victory for shareholder activism.
- Reuters
INSIGHT-Ripe for change? Activist investors eye food, consumer goods firms
In early 2021, investment management firm Artisan Partners sent an open letter to an incoming member of Danone's board, saying it had built a stake of more than 3% in the French food giant. "On almost every measure, Danone's performance has lagged," Artisan said, and called for change. About a month later, Danone's then-CEO and chairman, Emmanuel Faber, was ousted and its board overhauled in a high-profile victory for shareholder activism.
The TelegraphSlimfast suffers as dieters turn to Ozempic
Slimfast has suffered a drop in sales as dieters turn to blockbuster drugs such as Ozempic to lose weight.
